



State of Louisiana

Louisiana Department of Health
Bureau of Health Services Financing

MEMORANDUM

DATE: February 14, 2017

TO: All Louisiana Medicaid Providers

FROM: Jen Steele, Medicaid Director
Dr. SreyRam Kuy, Medicaid Chief Medical Officer

SUBJECT: Makena® and Compounded 17-P in Louisiana Medicaid

Thank you for caring for our Louisiana Medicaid patients. We appreciate you and all you do!

Improving birth outcomes is a priority for the Louisiana Department of Health and appropriate use of 17-hydroxyprogesterone is an important tool in preventing preterm births.

We would like to remind prescribers and pharmacists that Prior Authorization is NOT required for Makena® or compounded 17-P for Louisiana Medicaid patients. This includes both Fee for Service and all the Managed Care Organization Plans. Makena® Care Connection, an adherence support program from the manufacturer, is NOT required and should NOT be used for Louisiana Medicaid recipients..

The Department's goal is to provide access to Makena® and compounded 17-P with no barriers or paperwork for the prescribers to reduce the risk of preterm birth in women who have a history of singleton spontaneous preterm birth in Louisiana.

An informational bulletin with complete Billing and Ordering Guide has been posted at:
http://ldh.louisiana.gov/assets/docs/BayouHealth/Informational_Bulletins/2016/IB16-5.pdf

We appreciate your efforts in decreasing the risk of preterm birth in Louisiana and for your treatment and care of our Medicaid moms. If you have any issues obtaining Makena® or compounded 17-P for your patients, please call Paul Knecht (225) 342-2768 or the Pharmacy Help Desk (800) 437-9101 as a central point of contact.

Your continued support of the Louisiana Medicaid program efforts to coordinate care and improve health is greatly appreciated.

JS/SK/MBW/PSK

C: Healthy Louisiana Plans
Melwyn B. Wendt
Molina